Binding agents binding to PD-L1 and CD137 and use thereof

US11459395B2 · kind B2 · utility

Assignees

• GENMAB A/S · DK
• BIONTECH SE · DE

Inventors

• Isil Altintas · Utrecht, NL
• David Satijn · Utrecht, NL
• Rik RADEMAKER · Utrecht, NL
• Paul Parren · Utrecht, NL
• Ugur Sahin · Mainz, DE
• Friederike Gieseke · Mainz, DE
• Alexander Muik · Seeheim-Jugenheim, DE
• Christian GRUNWITZ · Mainz, DE
• Edward Norbert Van Den Brink · Amsterdam, NL
• Dennis VERZIJL · Amstelveen, NL

Key dates

• Filing date: Feb 10, 2021
• Grant date: Oct 4, 2022
• Expiry date: Feb 10, 2041

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/92
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to novel binding agents and their use in medicine. In particular, the invention relates to binding agents such as bispecific antibodies binding human PD-L1 and binding human CD137. The invention furthermore relates to uses of the antibodies of the invention and to methods, nucleic acid constructs and host cells for producing antibodies of the invention.